PAHC (68) INVA (75) ETON (62) OCUL (37) ⌘ Pro Terminal →

Structure Therapeutics Inc. (GPCR) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell GPCR stock right now?

Structure Therapeutics Inc. (GPCR) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.

Q: What is GPCR's 12-month price target and RQD AI Jury consensus?

GPCR's 12-month base price target is $20.36 (range $15.88 to $99.65), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$21.94 +2.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.98

Structure Therapeutics Inc. (GPCR) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $1.56B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.98 (+0.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GPCR)Realized 20D OHLCV Swing Band: ±12.3%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY GPCR SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.3% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.5 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$25.54-17.5% Next Q

Q2 (-2Q)

Grade D$21.08+0.5% Next Q

Q3 (-1Q)

Grade D$21.19+3.5% Next Q

Current

Grade D-$21.94-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GPCR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GPCR currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($33.44) and Max Pain ($23.04) forces dealer call-delta covering toward $99.65.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GPCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GPCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

26.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $21$21.94H: $95

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on GPCR

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-19.5% ROIC with 42.0% gross margin and -14.43% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

16/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like GPCR

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GPCR)

✓Walkthrough of GPCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GPCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -47.07%🛡️ HOLDING TREND SUPPORT

2026-10-30O $21.59H $22.36L $21.07C $21.94VOL 695.9K

RES: $53.05SUP: $19.30SMA50: $33.44SMA200: $49.06

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GPCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GPCR Butterfly Map → + Track GPCR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GPCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GPCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GPCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GPCR)

Health Care Rank #571 of 1016 ⚔️ PAHC vs GPCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GPCR vs. PAHC, INVA, ETON, OCUL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Structure Therapeutics Inc. (GPCR) ranks #571 by composite RQD confidence (42/100, grade D-) and #301 by equity capitalization ($1.56B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with GPCR at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GPCR ACTIVE Structure Therapeutics Inc.	D-	42/100	—	—	-19.5%	+2.14%	$1.56B	Benchmark Subject
PAHC Phibro Animal Health Corporation (Class A)	C+	68/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	/pahc-vs-gpcr →
INVA Innoviva Inc.	B	75/100	—	74.8%	14.7%	+0.90%	$1.54B	/inva-vs-gpcr →
ETON Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	/eton-vs-gpcr →
OCUL Ocular Therapeutix Inc.	D-	37/100	—	87.3%	-35.0%	+0.27%	$1.61B	/ocul-vs-gpcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001888886

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Structure Therapeutics Inc. (GPCR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$141.2M, operating cash flow of -$222.2M, and free cash flow of -$225.8M (-91.5% YoY). On the balance sheet, GPCR closed FY2025 with $1.58B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$141.2M	-$222.2M	-$225.8M	$1.58B	—
FY2024 (FY)	2024-12-31	$0	-$122.5M	-$116.6M	-$117.9M	$903.3M	—
FY2023 (FY)	2023-12-31	$0	-$89.6M	-$79.5M	-$79.5M	—	—

3. GPCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GPCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Structure Therapeutics Inc. (NASDAQ: GPCR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $21.94 (+2.14% 1D, market cap $1.56B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GPCR ranks #571 in composite RQD confidence.

How does GPCR compare to PAHC and INVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GPCR carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -19.5%. By comparison, PAHC (Phibro Animal Health Corporation (Class A)) holds a C+ grade (68/100 RQD, P/E 32.7x, ROIC 9.9%, cap $1.58B) and INVA (Innoviva Inc.) posts a B grade (75/100 RQD, P/E N/A, ROIC 14.7%, cap $1.54B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GPCR?

Per GPCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001888886), Structure Therapeutics Inc. generated $0 in revenue, -$141.2M in net income, and -$225.8M in free cash flow against $1.58B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GPCR trading relative to its 50-day, 200-day, and 52-week technical levels?

GPCR last traded at $21.94 (+2.14% on volume of 929,537 shares), positioning the stock -34.39% below its 50-day simple moving average ($33.44) and -55.28% below its 200-day simple moving average ($49.06). Across its 52-week range of $20.50 to $94.90, GPCR sits at the 1.9% percentile with a 14-day RSI of 26.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.3% ($19.24 to $24.64).

GPCR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell GPCR stock right now?

Structure Therapeutics Inc. (GPCR) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.

What is GPCR's 12-month price target and RQD AI Jury consensus?

GPCR's 12-month base price target is $20.36 (range $15.88 to $99.65), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: GPCR RQD Cockpit GPCR 12M Forecast GPCR Earnings & Move GPCR Dividends & DRIP GPCR Insiders & 13F GPCR Whale Options GPCR Profit Sankey GPCR News & Why